ANGION BIOMEDICA CORP (ANGN) Stock Price & Overview
NASDAQ:ANGN • US03476J1079
Current stock price
The current stock price of ANGN is 1 USD. Today ANGN is up by 2.04%. In the past month the price increased by 47.54%. In the past year, price decreased by -36.31%.
ANGN Key Statistics
- Market Cap
- 30.114M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.29
- Dividend Yield
- N/A
ANGN Stock Performance
ANGN Stock Chart
ANGN Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ANGN. When comparing the yearly performance of all stocks, ANGN is one of the better performing stocks in the market, outperforming 73.64% of all stocks.
ANGN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ANGN. While ANGN seems to be doing ok healthwise, there are quite some concerns on its profitability.
ANGN Earnings
ANGN Forecast & Estimates
6 analysts have analysed ANGN and the average price target is 1.53 USD. This implies a price increase of 53% is expected in the next year compared to the current price of 1.
For the next year, analysts expect an EPS growth of 34.37% and a revenue growth -100% for ANGN
ANGN Groups
Sector & Classification
ANGN Financial Highlights
Over the last trailing twelve months ANGN reported a non-GAAP Earnings per Share(EPS) of -1.29. The EPS increased by 38.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
ANGN Ownership
ANGN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 25.83 | 869.14B | ||
| JNJ | JOHNSON & JOHNSON | 17.83 | 555.642B | ||
| MRK | MERCK & CO. INC. | 22.11 | 289.223B | ||
| PFE | PFIZER INC | 9.14 | 156.544B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.38 | 120.728B | ||
| ZTS | ZOETIS INC | 16.71 | 51.606B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.57 | 28.443B | ||
| VTRS | VIATRIS INC | 5.91 | 17.315B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.49 | 11.825B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.651B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.206B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.087B | ||
| CORT | CORCEPT THERAPEUTICS INC | 83.11 | 4.929B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ANGN
Company Profile
Angion Biomedica Corp. operates as a biopharmaceutical company. The company is headquartered in Newton, Massachusetts and currently employs 3 full-time employees. The company went IPO on 2021-02-05. The firm is focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases and acute organ injuries. The Company’s product candidates and programs include ANG-3070, a highly selective oral tyrosine kinase receptor inhibitor (TKI) in development as a treatment for fibrotic diseases, a ROCK2 preclinical program targeted towards the treatment of fibrotic diseases, a CYP11B2 preclinical program targeted towards diseases related to aldosterone synthase dysregulation, and a CYP26 (retinoic acid metabolism) inhibitor program targeted towards a number of biopharmaceutical indications, including cancer, and ANG-3777, a hepatocyte growth factor (HGF) mimetic. Its ROCK2 program includes a number of highly selective, oral small molecule inhibitors of ROCK2 developed internally as a potential treatment for fibrotic and other diseases.
Company Info
IPO: 2021-02-05
ANGION BIOMEDICA CORP
7-57 Wells Avenue
Newton MASSACHUSETTS 11553 US
CEO: Jay R. Venkatesan
Employees: 3
Phone: 18573364001.0
ANGION BIOMEDICA CORP / ANGN FAQ
What does ANGN do?
Angion Biomedica Corp. operates as a biopharmaceutical company. The company is headquartered in Newton, Massachusetts and currently employs 3 full-time employees. The company went IPO on 2021-02-05. The firm is focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases and acute organ injuries. The Company’s product candidates and programs include ANG-3070, a highly selective oral tyrosine kinase receptor inhibitor (TKI) in development as a treatment for fibrotic diseases, a ROCK2 preclinical program targeted towards the treatment of fibrotic diseases, a CYP11B2 preclinical program targeted towards diseases related to aldosterone synthase dysregulation, and a CYP26 (retinoic acid metabolism) inhibitor program targeted towards a number of biopharmaceutical indications, including cancer, and ANG-3777, a hepatocyte growth factor (HGF) mimetic. Its ROCK2 program includes a number of highly selective, oral small molecule inhibitors of ROCK2 developed internally as a potential treatment for fibrotic and other diseases.
Can you provide the latest stock price for ANGION BIOMEDICA CORP?
The current stock price of ANGN is 1 USD. The price increased by 2.04% in the last trading session.
What is the dividend status of ANGION BIOMEDICA CORP?
ANGN does not pay a dividend.
What is the ChartMill technical and fundamental rating of ANGN stock?
ANGN has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is ANGION BIOMEDICA CORP (ANGN) stock traded?
ANGN stock is listed on the Nasdaq exchange.
What sector and industry does ANGION BIOMEDICA CORP belong to?
ANGION BIOMEDICA CORP (ANGN) operates in the Health Care sector and the Pharmaceuticals industry.
When does ANGION BIOMEDICA CORP (ANGN) report earnings?
ANGION BIOMEDICA CORP (ANGN) will report earnings on 2023-08-14.